肺肉瘤样癌辅助化疗:美国国家癌症数据库回顾性分析
本研究基于美国国家癌症数据库2004至2015年数据,回顾性分析1497例接受完全解剖性切除的肺肉瘤样癌(PSC)患者。多因素Cox回归和倾向匹配组Kaplan-Meier分析显示,辅助化疗与II期和III期患者5年总生存改善相关,但与I期患者无关。
要点
- 辅助化疗与II期和III期PSC切除后5年总生存改善相关。
- 辅助化疗与I期PSC患者生存改善无关。
- 接受辅助化疗与年龄、组织学类型和辅助放疗相关。
核心结论
- 辅助化疗与II期和III期肺肉瘤样癌切除后5年总生存改善相关,但与I期无关。
研究设计与样本
- 回顾性队列研究,查询美国国家癌症数据库2004至2015年诊断为PSC并接受完全解剖性切除的患者,最终纳入1497例。
主要发现
- 接受辅助化疗与年龄、组织学类型和接受辅助放疗相关。
- 多因素Cox分析和倾向匹配组Kaplan-Meier分析趋势一致:辅助化疗与II期和III期5年总生存改善相关,与I期无关。
临床怎么用
- 对于II期和III期PSC患者,完全切除后可考虑辅助化疗以改善生存。
- I期PSC患者辅助化疗未见生存获益,决策需个体化。
局限性
- 回顾性研究设计,可能存在选择偏倚和未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Pulmonary sarcomatoid carcinoma (PSC) is a rarely occurring variant of non-small cell lung cancer with sarcoma-like features. Compared with traditional non-small cell lung cancer, PSC patients typically present later and have poorer prognoses, irrespective of stage. The standard of care is resection, but guidelines for the use of adjuvant chemotherapy have not been established. To advance the development of evidence-based management algorithms for PSC after resection, a statistical analysis on a nationwide representative sample of patients was performed. METHODS: A retrospective cohort study was performed by querying the National Cancer Database for patients with a diagnosis of PSC between 2004 and 2015. Patients who received complete anatomical resection with or without adjuvant chemotherapy were included. Multivariable regression was used to detect factors associated with the receipt of adjuvant chemotherapy. Multivariable Cox regression of overall survival and Kaplan-Meier survival analysis on propensity-matched groups was conducted to study the association between adjuvant chemotherapy and prognosis. RESULTS: We included 1497 patients with PSC in the final analysis. Factors associated with receiving adjuvant chemotherapy were age, histology, and receipt of adjuvant radiation. The results of multivariable Cox analysis and Kaplan-Meier analysis on propensity matched groups yielded similar trends: adjuvant chemotherapy was associated with improved 5-year overall survival for stage II and III disease, but not for stage I disease. CONCLUSIONS: Multiple factors are associated with receipt of adjuvant chemotherapy for PSC, and this treatment appears to be associated with improved survival in stage II and stage III, but not stage I patients.
引用
- Abdallah HM, Martinez-Meehan D, Lutfi W, et al. Adjuvant chemotherapy for pulmonary sarcomatoid carcinoma: A retrospective analysis of the National Cancer Database. J Thorac Cardiovasc Surg. 2021. PMID: 33678508. doi:10.1016/j.jtcvs.2021.01.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。